Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.

The former health minister predicted a bright future for UK trials and outlined steps to ensure clinical research thrives.

Penumbra has developed a microprocessor with thrombus removal algorithms that, combined with audio-visual feedback, help ...

Zymeworks has dosed the first patient in its Phase I clinical trial of ZW191 aimed at treating advanced solid tumours.

The human version of ANK-101 is currently undergoing Phase I clinical trials in the US and Canada. Credit: ...

Intra-Cellular expects Caplyta to generate $665m-$685m in sales this year. Image credit: Lightspring / Shutterstock. Having raised the full-year sales guidance for Caplyta (lumateperone) a week ago, ...

With the new funding, Research Grid plans to invest in research and development, creating more AI automation and expanding its engineering teams. Credit: Collagery / Shutterstock. Research Grid has ...

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The community screening programme charts an effective, affordable framework for TB control in the Canadian province of ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Oak Hill Bio and Chiesi have enrolled the first European patient in a Phase IIb study for OHB-607, to prevent BPD in infants.